364 related articles for article (PubMed ID: 28655599)
21. An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens.
Parma G; Mancari R; Del Conte G; Scambia G; Gadducci A; Hess D; Katsaros D; Sessa C; Rinaldi A; Bertoni F; Vitali A; Catapano CV; Marsoni S; van de Velde H; Colombo N
Int J Gynecol Cancer; 2012 Jun; 22(5):792-800. PubMed ID: 22635029
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of pegylated liposomal Doxorubicin in combination with bortezomib for multiple myeloma: effects of adverse prognostic factors on outcome.
Bladé J; Sonneveld P; San Miguel JF; Sutherland HJ; Hajek R; Nagler A; Spencer A; Robak T; Lantz KC; Zhuang SH; Harousseau JL; Orlowski RZ;
Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):44-9. PubMed ID: 21454189
[TBL] [Abstract][Full Text] [Related]
23. Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors.
Turner JG; Dawson JL; Grant S; Shain KH; Dalton WS; Dai Y; Meads M; Baz R; Kauffman M; Shacham S; Sullivan DM
J Hematol Oncol; 2016 Aug; 9(1):73. PubMed ID: 27557643
[TBL] [Abstract][Full Text] [Related]
24. Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma.
Richardson PG; Hofmeister CC; Raje NS; Siegel DS; Lonial S; Laubach J; Efebera YA; Vesole DH; Nooka AK; Rosenblatt J; Doss D; Zaki MH; Bensmaine A; Herring J; Li Y; Watkins L; Chen MS; Anderson KC
Leukemia; 2017 Dec; 31(12):2695-2701. PubMed ID: 28642620
[TBL] [Abstract][Full Text] [Related]
25. An open-label phase I/II study of cyclophosphamide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed myeloma.
Nishihori T; Baz R; Shain K; Kim J; Ochoa-Bayona JL; Yue B; Sullivan D; Dalton W; Alsina M
Eur J Haematol; 2015 Nov; 95(5):426-35. PubMed ID: 25600676
[TBL] [Abstract][Full Text] [Related]
26. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.
Dimopoulos MA; Goldschmidt H; Niesvizky R; Joshua D; Chng WJ; Oriol A; Orlowski RZ; Ludwig H; Facon T; Hajek R; Weisel K; Hungria V; Minuk L; Feng S; Zahlten-Kumeli A; Kimball AS; Moreau P
Lancet Oncol; 2017 Oct; 18(10):1327-1337. PubMed ID: 28843768
[TBL] [Abstract][Full Text] [Related]
27. A phase 1 dose-escalation study of filanesib plus bortezomib and dexamethasone in patients with recurrent/refractory multiple myeloma.
Chari A; Htut M; Zonder JA; Fay JW; Jakubowiak AJ; Levy JB; Lau K; Burt SM; Tunquist BJ; Hilder BW; Rush SA; Walker DH; Ptaszynski M; Kaufman JL
Cancer; 2016 Nov; 122(21):3327-3335. PubMed ID: 27433944
[TBL] [Abstract][Full Text] [Related]
28. Synergistic anticancer activity of combined histone deacetylase and proteasomal inhibitor-loaded zein nanoparticles in metastatic prostate cancers.
Thapa RK; Nguyen HT; Jeong JH; Shin BS; Ku SK; Choi HG; Yong CS; Kim JO
Nanomedicine; 2017 Apr; 13(3):885-896. PubMed ID: 27993720
[TBL] [Abstract][Full Text] [Related]
29. Vorinostat plus bortezomib for the treatment of relapsed/refractory multiple myeloma: a case series illustrating utility in clinical practice.
Mazumder A; Vesole DH; Jagannath S
Clin Lymphoma Myeloma Leuk; 2010 Apr; 10(2):149-51. PubMed ID: 20371450
[TBL] [Abstract][Full Text] [Related]
30. A phase I/II study of KW-2478, an Hsp90 inhibitor, in combination with bortezomib in patients with relapsed/refractory multiple myeloma.
Cavenagh J; Oakervee H; Baetiong-Caguioa P; Davies F; Gharibo M; Rabin N; Kurman M; Novak B; Shiraishi N; Nakashima D; Akinaga S; Yong K
Br J Cancer; 2017 Oct; 117(9):1295-1302. PubMed ID: 28873084
[TBL] [Abstract][Full Text] [Related]
31. Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study.
Voorhees PM; Orlowski RZ; Mulkey F; Watson P; Geyer S; Sanford BL; Bennett E; Chanan-Khan AA; Bloomfield CD; Larson RA
Br J Haematol; 2015 Nov; 171(3):373-7. PubMed ID: 26202857
[TBL] [Abstract][Full Text] [Related]
32. Weekly bortezomib, pegylated liposomal doxorubicin, and dexamethasone is a safe and effective therapy for elderly patients with relapsed/refractory multiple myeloma.
Gozzetti A; Fabbri A; Oliva S; Marchini E; Bocchia M; Defina M; Lauria F
Clin Lymphoma Myeloma Leuk; 2010 Feb; 10(1):68-72. PubMed ID: 20223732
[TBL] [Abstract][Full Text] [Related]
33. Extended follow-up of outcome measures in multiple myeloma patients treated on a phase I study with bortezomib and pegylated liposomal doxorubicin.
Biehn SE; Moore DT; Voorhees PM; Garcia RA; Lehman MJ; Dees EC; Orlowski RZ
Ann Hematol; 2007 Mar; 86(3):211-6. PubMed ID: 17146676
[TBL] [Abstract][Full Text] [Related]
34. Liposomal doxorubicin in combination with bortezomib for relapsed or refractory multiple myeloma.
Ning YM; He K; Dagher R; Sridhara R; Farrell AT; Justice R; Pazdur R
Oncology (Williston Park); 2007 Nov; 21(12):1503-8; discussion 1511, 1513, 1516 passim. PubMed ID: 18077994
[TBL] [Abstract][Full Text] [Related]
35. Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma.
San-Miguel JF; Richardson PG; Günther A; Sezer O; Siegel D; Bladé J; LeBlanc R; Sutherland H; Sopala M; Mishra KK; Mu S; Bourquelot PM; Victoria Mateos M; Anderson KC
J Clin Oncol; 2013 Oct; 31(29):3696-703. PubMed ID: 24019544
[TBL] [Abstract][Full Text] [Related]
36. A phase IIb trial of vorinostat in combination with lenalidomide and dexamethasone in patients with multiple myeloma refractory to previous lenalidomide-containing regimens.
Sanchez L; Vesole DH; Richter JR; Biran N; Bilotti E; McBride L; Anand P; Ivanovski K; Siegel DS
Br J Haematol; 2017 Feb; 176(3):440-447. PubMed ID: 27859001
[TBL] [Abstract][Full Text] [Related]
37. Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma.
Mu S; Kuroda Y; Shibayama H; Hino M; Tajima T; Corrado C; Lin R; Waldron E; Binlich F; Suzuki K
Eur J Clin Pharmacol; 2016 Feb; 72(2):153-61. PubMed ID: 26494130
[TBL] [Abstract][Full Text] [Related]
38. Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma.
Richardson PG; Laubach JP; Lonial S; Moreau P; Yoon SS; Hungria VT; Dimopoulos MA; Beksac M; Alsina M; San-Miguel JF
Expert Rev Anticancer Ther; 2015; 15(7):737-48. PubMed ID: 26051506
[TBL] [Abstract][Full Text] [Related]
39. Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy.
Baz R; Walker E; Karam MA; Choueiri TK; Jawde RA; Bruening K; Reed J; Faiman B; Ellis Y; Brand C; Srkalovic G; Andresen S; Knight R; Zeldis J; Hussein MA
Ann Oncol; 2006 Dec; 17(12):1766-71. PubMed ID: 16980599
[TBL] [Abstract][Full Text] [Related]
40. Bortezomib in combination with pegylated liposomal doxorubicin for the treatment of multiple myeloma.
Manochakian R; Miller KC; Chanan-Khan AA
Clin Lymphoma Myeloma; 2007 Jan; 7(4):266-71. PubMed ID: 17324333
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]